Skip To Main Content
For US Healthcare Professionals

Wet Age-related Macular Degeneration (AMD) Diabetic Macular Edema (DME) Macular Edema following Retinal Vein Occlusion (RVO)

Questions?1-833-393-4363

Support for care partners

If your loved one is living with macular edema following RVO, a few simple changes can make a big difference in their life

When someone finds out they have macular edema following RVO, they may feel overwhelmed and scared about their treatment. You can play an important role in helping manage their vision challenges and easing their concerns.

Here are some everyday challenges your loved one may face and tips on how you can help them:

WHAT YOUR LOVED ONE MAY SAY

Table (icon)

“I keep bumping into the table.”

Lamp (icon)

“It’s dark in here.”

Magnifying (icon)

“This print is too small.”

Keys (icon)

“I can’t find my keys.”

HOW YOU CAN HELP

HOW
YOU
CAN HELP

Make it easy to move around the home. Create clear pathways across rooms, with easy access to doors and windows.

Make it easy to see around the home—sunlight and natural light are the best. Utilize the light from your windows and use light curtains that are easy to pull up/back.

Use tools to help make reading easier:

  • Illuminated reading devices
  • Voice assistants, such as Alexa, Siri, and Google Assistant
  • Light-up pens/readers for reading menus at restaurants
  • High-contrast e-readers
  • Adjusting the font size on their cellular device

Develop a system for storing and arranging commonly used items such as:

  • Jackets
  • Reading glasses
  • Keys
  • Toothbrushes
  • Shoes

This will make it easier for someone with macular edema following RVO to find them.

WHAT YOUR LOVED ONE MAY SAY

HOW YOU
CAN HELP

Table (icon)

“I keep bumping into the table.”

Make it easy to move around the home. Create clear pathways across rooms, with easy access to doors and windows.

Lamp (icon)

“It’s dark in here.”

Make it easy to see around the home—sunlight and natural light are the best. Utilize the light from your windows and use light curtains that are easy to pull up/back.

Magnifying (icon)

“This print is too small.”

Use tools to help make reading easier:

  • Illuminated reading devices
  • Voice assistants, such as Alexa, Siri, and Google Assistant
  • Light-up pens/readers for reading menus at restaurants
  • High-contrast e-readers
  • Adjusting the font size on their cellular device
Keys (icon)

“I can’t find my keys.”

Develop a system for storing and arranging commonly used items such as:

  • Jackets
  • Reading glasses
  • Keys
  • Toothbrushes
  • Shoes

This will make it easier for someone with macular edema following RVO to find them.

Sign up for support to receive helpful information about macular edema following RVO and treatment with VABYSMO®

SIGN UP NOW
GET ANSWERS TO FREQUENTLY ASKED QUESTIONS

IMPORTANT SAFETY INFORMATION

What is VABYSMO?

VABYSMO (faricimab-svoa) is a prescription medicine given by injection into the eye used to treat adults with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO).

Do not receive VABYSMO if you:

  • Have an infection in or around your eye. 
  • Have active swelling around your eye that may include pain and redness. 
  • Are allergic to VABYSMO or any of the ingredients in VABYSMO.

What is the most important information I should know about VABYSMO?

  • Injections like the one for VABYSMO can cause an eye infection (endophthalmitis), separation of layers of the retina (retinal detachment), or inflammation in the eye that can lead to vision loss. Call your healthcare provider right away if your eye becomes red, sensitive to light, or you have a change or loss of vision.
  • VABYSMO may cause a temporary increase in pressure in the eye (intraocular pressure), which occurs within 60 minutes after receiving the eye injection.
  • Although not common, VABYSMO patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes (thromboembolic events). In clinical studies for wet AMD during the first year, 7 out of 664 patients treated with VABYSMO reported such an event. In clinical studies for DME from baseline to week 100, 64 out of 1,262 patients treated with VABYSMO reported such an event. In clinical studies for RVO during 6 months, 7 out of 641 patients treated with VABYSMO reported such an event.
  • Severe inflammation of vessels in the retina has happened for patients treated with VABYSMO. Call your healthcare provider immediately if you experience a change in vision.

Before receiving VABYSMO, tell your healthcare provider about all of your medical conditions, including if you:

  • Are pregnant or plan to become pregnant. Based on how VABYSMO interacts with your body, there may be a potential risk to your unborn baby. You should use birth control before your first injection, during your treatment with VABYSMO, and for 3 months after your last dose of VABYSMO.
  • Are breastfeeding or plan to breastfeed. It is not known if VABYSMO passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive VABYSMO.
  • Are taking any medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tell your healthcare provider about all the medicines you take.

What should I avoid while receiving VABYSMO? 

  • Your vision may be impaired after receiving an eye injection or after an eye exam. Do not drive or use machinery until your vision has recovered sufficiently. 

What are the most common side effects with VABYSMO?

  • The most common side effects with VABYSMO were cataract and blood on the white of the eye (conjunctival hemorrhage).
  • These are not all the possible side effects of VABYSMO.

Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-888-835-2555. 

Please see the VABYSMO full Prescribing Information for additional Important Safety Information.